Long-term efficacy and safety of upadacitinib in patients with polyarticular-course juvenile idiopathic arthritis: 48 week results from the SELECT-YOUTH open-label study

OBJECTIVES: The phase 1 SELECT-YOUTH trial demonstrated efficacy and safety of upadacitinib for pcJIA in pediatric patients. This second interim analysis incorporates the results from an additional cohort providing efficacy results up to 48 weeks and cumulative safety up to 156 weeks. METHODS: 122 patients with pcJIA, aged 2 to < 18 years received upadacitinib, dosed either twice-daily oral solution or once-daily extended-release tablet, based on body weight. Analyses included patients who received at least one dose. Efficacy and safety outcomes were evaluated through week 156 using as observed and non-responder imputation methods. Efficacy was reported up to 48 weeks; safety was assessed at all study time points. Efficacy included JIA-ACR 30/50/70/90/100 response rates, Juvenile Arthritis Disease Activity Score (JADAS)-27, C-HAQ, and pain. RESULTS: At 48 weeks, JIA-ACR response rates were: 96.3% (JIA-ACR30), 93.6% (JIA-ACR50), 89.0% (JIA-ACR70), 72.5% (JIA-ACR90), 57.8% (JIA-ACR100). Low disease activity (JADAS-27 [CRP] ≤ 3.8) was achieved by 79.4%, with 49.5% reaching inactive disease status (JADAS-27 [CRP] ≤ 1). C-HAQ change from baseline to week 48 was -0.64 (n = 108) and rapid improvement in pain was evident by week 12 and persisted throughout 48 weeks. Treatment-emergent adverse events were generally mild to moderate, occurring at 499.6 events per 100 patient-years (E/100 PY; n = 122). Most frequent events (per 100 PY) of special interest were hepatic disorders (7.5), bone fractures (4.3), and CPK elevation (3.5). No deaths occurred. CONCLUSIONS: In the SELECT-YOUTH trial, bodyweight-based dosing of upadacitinib maintained efficacy in pediatric patients with pcJIA, and its safety profile was consistent with established safety profile. TRIAL REGISTRATION: ClinicalTrials.gov: NCT03725007; EUDRACT: 2018-000715-25.

Authors

Institutions

Publication Details

Journal
Rheumatology
Published
2026-11-12
DOI
https://doi.org/10.1093/rheumatology/keag595
Primary Topic
Autoimmune and Inflammatory Disorders Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Long-term efficacy and safety of upadacitinib in patients with polyarticular-course juvenile idiopathic arthritis: 48 week results from the SELECT-YOUTH open-label study

Athimalaipet Vaidyanathan Ramanan, Ivan Foeldvari, Hermine I. Brunner, Shuai Hao et al.
Rheumatology
Autoimmune and Inflammatory Disorders Research
article

Long-term efficacy and safety of upadacitinib in patients with polyarticular-course juvenile idiopathic arthritis: 48 week results from the SELECT-YOUTH open-label study

Athimalaipet Vaidyanathan Ramanan, Ivan Foeldvari, Hermine I. Brunner, Shuai Hao, Jordi Antón, Sebastian Meerwein, Miriam Avadisian, Gerd Horneff, Ana Belén Romero, Kristina Unnebrink, Lauren D Smith, Michael Sherenian, Masaaki Mori
article en

Abstract

OBJECTIVES: The phase 1 SELECT-YOUTH trial demonstrated efficacy and safety of upadacitinib for pcJIA in pediatric patients. This second interim analysis incorporates the results from an additional cohort providing efficacy results up to 48 weeks and cumulative safety up to 156 weeks. METHODS: 122 patients with pcJIA, aged 2 to < 18 years received upadacitinib, dosed either twice-daily oral solution or once-daily extended-release tablet, based on body weight. Analyses included patients who received at least one dose. Efficacy and safety outcomes were evaluated through week 156 using as observed and non-responder imputation methods. Efficacy was reported up to 48 weeks; safety was assessed at all study time points. Efficacy included JIA-ACR 30/50/70/90/100 response rates, Juvenile Arthritis Disease Activity Score (JADAS)-27, C-HAQ, and pain. RESULTS: At 48 weeks, JIA-ACR response rates were: 96.3% (JIA-ACR30), 93.6% (JIA-ACR50), 89.0% (JIA-ACR70), 72.5% (JIA-ACR90), 57.8% (JIA-ACR100). Low disease activity (JADAS-27 [CRP] ≤ 3.8) was achieved by 79.4%, with 49.5% reaching inactive disease status (JADAS-27 [CRP] ≤ 1). C-HAQ change from baseline to week 48 was -0.64 (n = 108) and rapid improvement in pain was evident by week 12 and persisted throughout 48 weeks. Treatment-emergent adverse events were generally mild to moderate, occurring at 499.6 events per 100 patient-years (E/100 PY; n = 122). Most frequent events (per 100 PY) of special interest were hepatic disorders (7.5), bone fractures (4.3), and CPK elevation (3.5). No deaths occurred. CONCLUSIONS: In the SELECT-YOUTH trial, bodyweight-based dosing of upadacitinib maintained efficacy in pediatric patients with pcJIA, and its safety profile was consistent with established safety profile. TRIAL REGISTRATION: ClinicalTrials.gov: NCT03725007; EUDRACT: 2018-000715-25.

Rheumatology
Cincinnati Children's Hospital Medical Center (US), Hospital Sant Joan de Déu Barcelona (ES), St. Marianna University School of Medicine (JP), Bristol Royal Hospital for Children (GB), AbbVie (United States) (US), University of Bristol (GB), Asklepios Klinik Sankt Augustin (DE), AbbVie (Germany) (DE), AbbVie (Spain) (ES), University Hospital Cologne (DE), AbbVie Canada (Canada) (CA), Institute of Biomedical Engineering (Japan) (JP), University of Cincinnati (US), Universitat de Barcelona (ES)
Autoimmune and Inflammatory Disorders Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon